GPCR 241115 37.50P (GPCR241115P37500) Stock Options, News & Quotes

US OptionsDetailed Quotes

GPCR241115P37500

Watchlist

2.85
-0.10-3.39%

15min DelayClose Oct 25 16:00 ET

2.85High2.65Low

Intraday

5D
Daily

News

Top Small-cap Stock Picks From Morgan Stanley Following the Group's Upgrade to Neutral
Seeking AlphaOct 21 14:52 ET
BMO Capital Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $100
Moomoo NewsOct 21 08:31 ET · Ratings
Consumer, Labor Groups Urge FTC to Block Catalent Sale to Novo Nordisk - Report
Seeking AlphaOct 17 15:30 ET
10 Health Care Stocks With Whale Alerts In Today's Session
BenzingaOct 16 13:35 ET
Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect?
Zacks Oct 9 09:05 ET
Obesity Drugs Seen Costing Medicare $35 Billion Through 2034
BNN BloombergOct 8 14:48 ET

Comments

104266827

Sep 23 07:37

still uptrend..go buy target price $65

Share Your Profit/Loss

Jensen 108

Sep 13 11:34

this one so hard to achieve 10% above. profit taken first.

Share Your Profit/Loss

Jensen 108

Aug 13 09:44

$Structure Therapeutics (GPCR.US)$ hopefully the uptrend continues

Meltyy

Jul 17 22:40

Smid-cap obesity stocks hit by $RHHBY positive Ph1 data for oral GLP-1 obesity drug ⚠️

$ROCHE HOLDING AG (RHHBY.US)$
📣 Roche News Snippet:
» CT-996 led to significant weight loss (-7.3%) after 4 weeks 🆚 placebo (-1.2%)
» data supports once-daily oral dosing regimen
» Safety profile was similar to other GLP-1 drugs; no unexpected safety issues observed
Did you see today's sell-off? 🔴
$Eli Lilly and Co (LLY.US)$ $Novo-Nordisk A/S (NVO.US)$ $Structure Therapeutics (GPCR.US)$ $Viking Therapeutics (VKTX.US)$ $Lipocine (LPCN.US)$

frankinglily

Jul 12 03:26

Is the diet pill market too profitable to lose?

Why do you think $Pfizer (PFE.US)$ decided to progress with Danuglipron? (Can't give up this huge market?
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co (LLY.US)$ Orforglipron and $Structure Therapeutics (GPCR.US)$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA